New-generation anticoagulant agents pose risks in treatment of acute coronary syndromes: The potential ischemic benefits of novel oral antiplatelet therapy following an acute coronary syndrome (ACS) may be offset by a significant increase in major bleeding events, according to a meta-analysis recently published in the Archives of Internal Medicine.
Special Report on Cardiovascular Disease